Relationships Between the Adverse Effects of Drugs and Genetic Polymorphism in Genes Encoding Drug Metabolizing Enzymes
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Levy G
. Pharmacokinetics of salicylate in man. Drug Metab Rev. 1979; 9(1):3-19.
DOI: 10.3109/03602537909046431.
View
2.
van Oijen M, Huybers S, Peters W, Drenth J, Laheij R, Verheugt F
. Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid. Br J Clin Pharmacol. 2005; 60(6):623-8.
PMC: 1884887.
DOI: 10.1111/j.1365-2125.2005.02495.x.
View
3.
Kuehl G, Bigler J, Potter J, Lampe J
. Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos. 2005; 34(2):199-202.
DOI: 10.1124/dmd.105.005652.
View
4.
Bigler J, Whitton J, Lampe J, Fosdick L, Bostick R, Potter J
. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001; 61(9):3566-9.
View
5.
McGreavey L, Turner F, Smith G, Boylan K, Bishop D, Forman D
. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics. 2005; 15(10):713-21.
DOI: 10.1097/01.fpc.0000174786.85238.63.
View